All MSVA antibodies are validated for IHC on TMA's containing 76 different normal
tissues and numerous cancer tissue types
Recently, MS Validated Antibodies designed an MTAP optimized antibody
that has been pivotal to dissect the prevalence of MTAP expression
loss in human cancer in the study of
Gorbokon et al. Am J Surg Pathol. 2024:
1) MTAP loss was observed in 83 of 149 tumor categories;
2) Homozygous MTAP deletion was found in 90% to 100% of cases;
with MTAP expression loss in most tumor categories
3) Complete specificity for MTAP and an excellent signal
to noise ratio was observed for the antibody MSVA-741R.
The data provided by Gorbokon et al. have been compiled into
informative graphical representations on the MSVA website:
https://ms-validatedantibodies.com/product/mtap-msva-741r/
